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Hyperglycemia and development of glomerular pathology: Diabetes
compared with galactosemia. Dogs were randomly assigned to experi-
mental galactosemia or diabetes, or to a normal untreated group, and
diabetic animals were then randomly assigned to either poor or good
glycemic control. At five years duration, kidneys from the animals were
compared by quantitative stereology. Glomerulopathy appeared in the
poor control diabetes group, and the thickness of glomerular capillary
basement membrane, the glomerular tuft volume, and the fraction of
glomerulus occupied by mesangium were each significantly greater than
normal. The capillary filtering surface area per glomerulus was supra-
normal also, but nonetheless was subnormal relative to glomerular
volume. The development of glomerulopathy was significantly inhibited
in dogs assigned to good glycemic control. In galactosemic animals, the
basement membrane thickness was greater than normal, but the gb-
merular volume, fractional and absolute volumes of mesangium, and
capillary filtering surface area remained normal. The polyol concentra-
tion in renal cortex seemed elevated by galactosemia no less than by
diabetes, and was highest in galactosemia. The galactosemic animals
are known to have developed a retinopathy morphologically compara-
ble to that of diabetic patients and diabetic dogs. Thus, sequelae of
hyperglycemia sufficient to produce glomerular basement membrane
thickening and retinopathy proved not necessarily sufficient to produce
the mesangial expansion and gbomerular hypertrophy typical of diabe-
tes.
Hyperglycemia, the principal symptom of diabetes mellitus,
is of uncertain significance in the etiology of diabetic nephrop-
athy. Elevation of the blood glucose concentration can alter
renal function, and has been shown to increase glomerular
filtration rate (GFR) and renal plasma flow (RPF), and via
nonenzymatic glycation of proteins, might increase the binding
of plasma proteins to glomerular basement membrane and alter
protein excretion [1—5]. Elevation of tissue polyoi concentra-
tion, another of the sequelae of hyperglycemia, possibly con-
tributes to such functional changes, and diabetes-induced ab-
normalities of renal function in rats reportedly may be inhibited
by pharmacologically inhibiting polyol production [6, 7]. To
what extent the anatomic renal lesions of diabetes are a result of
hyperglycemia and its sequelae is less clear. Thickening of
glomerular basement membrane has been reportedly produced
in nondiabetic mice by injections of nonenzymatically glycated
protein, but this finding has been disputed [8, 9].
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Elevation of the blood concentration of an isomer of glucose,
D-galactose, is known to be capable of reproducing many of the
complications of diabetes in the retina, lens, peripheral nerve,
and cornea [10, 11]. Retinal microaneurysms and other vascular
lesions characteristic of diabetic retinopathy are elicited in dogs
by experimental galactosemia [12]. Renal histology, in contrast,
has seemed upon light microscopy to be little affected [13].
Experimental galactosemia of five years duration apparently
failed to elicit the nephropathy seen in dogs diabetic equally
long, notwithstanding elevations of tissue polyol as great or
greater than seen in diabetic dogs. In the present report, effects
of long-term galactosemia on the ultrastructure of the renal
glomerulus have been quantitatively evaluated in dogs and
compared with the effects of diabetes.
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Methods
Healthy adult dogs (1-½ to 2-'/2 years old) were randomly
assigned to be made diabetic or fed a 30% galactose diet [12], or
to remain as normal untreated (control) animals. The dogs were
random source animals of mixed breeds. Diabetes was induced
by injection of alloxan monohydrate intravenously, and after a
brief interval of hyperglycemia to insure that the animals were
comparably insulin-deficient, the diabetics were randomly as-
signed to either poor glycemic control or good glycemic control
as described previously [14]. The poor control group received
unlimited food with insulin once daily at a dosage inadequate to
prevent chronic hyperglycemia and glucosuria, whereas the
good control group received a measured diet with insulin twice
daily at dosages chosen so as to minimize hyperglycemia and
glucosuria. Hemoglobin A1 (HbA1) was measured two to four
times per year using minicolumns (Isolab, Inc., Akron, Ohio),
after incubation to remove labile adducts. Blood glucose and
plasma galactose concentrations have been reported previously
[12].
Morphometry
At 60 months of study, animals were anesthetized with
pentobarbital and, after tissue samples had been removed, were
killed. Samples of renal cortex from mid-kidney were fixed for
light microscopy in 10% neutral formalin, and for electron
microscopy in 4% phosphate buffered glutaraldehyde followed
by post-fixation in 1% osmium tetroxide. Ultrathin sections of
the centermost gbomerulus from three different epon blocks
were placed on Butvar-coated copper slot grids (1 X 2 mm),
stained with uranyl acetate and lead citrate, and viewed in a
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Fig. 1. Glomerular capillaries from dogs at 60 months of study: (a) normal, (b) galactosemia, (c) alloxan diabetes with poor glycemic control, (d)
alloxan diabetes with good glycemic control. The basement membrane (r) ofperipheral capillaries is thicker than normal in galactosemia and in
poorly controlled diabetes. Large podocyte processes such as shown in Ic were common in poorly controlled diabetics, and possibly represent
fusion of foot processes. The micrographs illustrate the magnification used for the morphometric analyses, but include only 14% of the area of each
print analyzed. (x 17,270)
JEOL 100 CX electron microscope (JEOL, Tokyo, Japan).
Glomeruli were randomly entered, and then 15 to 25 evenly
spaced micrographs were taken and printed at a final magnifi-
cation of about 18,000x [151. A calibration grid was photo-
graphed each day along with the glomeruli. Obliterated glomer-
uli were not studied (although none were encountered in these
epon blocks).
Glomerular volume was determined from sections (4 pm) of
formalin-fixed paraffin-embedded kidney. The tissue sections
were stained with periodic acid-Schiff and hematoxylin, and
viewed in a microscope with a camera lucida attachment.
Outlines of glomerular tuft from 25 sequential glomeruli were
traced onto paper, and the area of the tuft profile was deter-
mined using computer-assisted morphometry. Distances from a
calibrated micrometer slide also were traced onto paper for use
in calibrating the glomerular area measurements. The mean
glomerular volume was calculated from mean glomerular area
as described by Hirose and coworkers [16].
Fractional volume (volume density) of each glomerular com-
ponent was determined from the electron photomicrographs
Table 1. Glycated hemoglobin and glycosuria of diabetic dogs and
experimentally galactosemic dogs studied 5 years (mean SD)
Hemoglobin Glycosuria
A1 % sugar-
N % g/kg/day free days
Normal 9 5.9 0.3 0 100
Diabetes
Good control 6 6.1 0.7 <1 68 II
Poor control 7 10.8 1.3 10.8 4.6 0
Galactosemia 5 6.8 0.2 2.5 0.4 0
using a 77 point grid [15]. Total volume per glomerulus of each
glomerular component was calculated from fractional volumes
and average glomerular volume for each animal. Capillary
filtering surface area relative to glomerular volume (surface
density of the filtration surface, Sly), and capillary length
relative to glomerular volume (LIV) were determined by stan-
dard stereological methods [15, 17]. Capillary filtering surface
area per glomerulus and capillary length per glomerulus were
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Table 2. Glomerular morphometry in diabetic dogs and experimentally galactosemic dogs studied 5 years (mean SD)
Normal
Diabetes
GalactosemiaGood control Poor control
N 9 6 7 5
Glomerular tuft vol 2.0 0.6 2.5 0.9 5.1 1.0° 1.9 0.4
— x 106
Mesangium, volume 0.31 0.21 0.43 0.20 1.08 O.45°° 0.24 0.13
pm3 X 106
Mesangium, volume 14 6 18 3 25 10" 11 4
% of glomerulus
Mesangial matrix, vol 9 3 Il 3 16 6 8.0 3
% of glom
Endothelium, vol 0.17 0.08 0.21 0.08 0.36 0.10 0.16 0.05
un3 x 106
Epithelium, vol 0.36 0.13 0.42 0.19 0.74 0.24a,1 0.40 0.08
.unh x 10
Capillary surface area mm2 0.33 0.09 0.38 0.12 0.60 0.l8 0.31 0.07
S/V m' 0.17 0.02 0.16 0.02 0.12 003ad 0.16 0.01
Capillary basement 361 76 416 34 644 79a.c 472 90b
membrane width nm
a P < 0.01 compared with normal
b P < 0.05 compared with normal
P < 0.01 compared with diabetes good controld P < 0.05 compared with diabetes good control
calculated as the product of average glomerular volume and S/V
or L/V, respectively. Thickness of glomerular peripheral capil-
lary basement membrane was determined by the orthogonal
intercept method [181.
Polyol accumulation
In an ancillary experiment, dogs were made galactosemic
(N = 3) or diabetic (poor glycemic control, N = 4) as described
above or were kept as normal controls (N 4), and were killed
after two to four months of study. Fresh kidney slices were
frozen at —80°C for assay of polyol concentration in renal
cortex. Polyol was assayed by gas chromatography in the case
of galactosemia (mostly galactitol), or by enzymatic methods
(to achieve the desired sensitivity for sorbitol) in tissue from
diabetic and normal animals [19, 201. The level of renal sorbitol
was similar in the two methods.
Group comparisons were made using parametric methods
(ANOVA followed by a Tukey-Kramer test) or nonparametric
methods (Kruskal-Wallis followed by Mann-Whitney U tests of
HbA1 concentration and tissue polyol concentration). Data are
reported as mean SD.
Results
Diabetic dogs assigned to the poor control group developed
chronic hyperglycemia, glycosuria, polyuria, and hyperphagia,
and their mean HbA, concentration for the five years of study
was significantly greater than normal (P < 0.01, Table 1, Fig. 1).
In diabetic dogs assigned to good control, such metabolic
abnormalities were absent or minimal and HbAJ was compara-
ble to normal. Nondiabetic animals fed the galactose-rich diet
showed levels of HbA, significantly greater than normal (P <
0.05) although less than the value for diabetics in poor control.
Poor control of diabetes resulted in glomerular hypertrophy
and mesangial expansion (Table 2). The volume of the glomer-
ulus greatly exceeded that of normal dogs and, moreover, the
mesangium was disproportionately enlarged and occupied a
greater than normal fraction of the glomerular volume. The
absolute volume of mesangium, accordingly, also exceeded
normal. The increase in the fractional volume of mesangium
involved increases in the fractional volumes of both the mesan-
gial cells and matrix. The mesangium's fractional volume varied
appreciably between animals, about 6 to 23% in normal dogs
and 9 to 34% in poorly controlled diabetics. Other glomerular
components in the poorly controlled diabetics (such as, capil-
lary endothelium and visceral epithelium) also showed signifi-
cant increases in absolute volume, and the capillary basement
membrane was significantly thicker than normal. Capillary
filtering surface density (Sly), was subnormal in the poor
control group, but the reduction seems due to glomerular
hypertrophy rather than to a loss of filtering surface area. The
filtering surface's absolute area in the poor control group was,
in fact, greater than normal. The ratio of capillary length to
glomerular volume (L/V) was not abnormal in any group (data
not shown).
Good glycemic control inhibited the development of the
above glomerular abnormalities in diabetes. The good control
group differed significantly from the poor control group, and not
from normal, with respect to basement membrane thickness,
glomerular volume, capillary filtering surface area per glomer-
ulus, capillary length per glomerulus, S/V ratio, and volume
occupied by endothelium and epithelium (Table 2). The fraction
of glomerulus occupied by mesangium in the good control group
was less than in poor controls, although not to a statistically
significant degree.
In contrast to the severe glomerulopathy seen in chronically
hyperglycemic diabetic dogs, the renal glomerulus of dogs
galactosemic for five years seemed little affected. The glomer-
ulus in galactosemia was not hypertrophic and was not signifi-
cantly different from normal with respect to either the fractional
volume or absolute volume (per glomerulus) of mesangium,
endothelium or epithelium. Neither the S/V ratio nor the total
capillary filtering surface area was abnormal. Nevertheless, the
capillary basement membrane was significantly thicker than in
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Table 3. Polyol concentration in renal cortex of dogs diabetic (poor
glycemic control) or galactosemic 2 to 4 months (mean SD)
N nmol/mg proteina
Normal 4 0.23 0,05
Diabetes 4 0.43 0.08
Galactosemia 3 6.0 1.2
a Measured as sorbitol in normals and diabetics, and galactitol in
galactosemics
normal animals. The capillary basement membrane was not as
thick as in the diabetic poor control group (P < 0.01).
In an ancillary study of polyol concentration in the renal
cortex, diabetes of two to four months duration was shown to
result in tissue polyol (sorbitol) levels significantly greater than
in normal dogs (P <0.05; Table 3). Galactosemic (nondiabetic)
dogs had tissue polyol (galactitol) concentrations several-fold
greater than those of normal or diabetic dogs.
Discussion
Diabetic dogs in poor glycemic control develop a nephrop-
athy closely resembling that characteristic of diabetes in pa-
tients. The renal abnormalities include nephromegaly, mesan-
gial expansion, glomerular obliteration, occasional exudative
deposits and mesangial nodules, and excessive excretion of
protein [13, 21—24]. In addition, the glomerular volume and
capillary filtering surface area become greater than normal in
diabetic dogs, as is the case also in diabetic patients prior to the
appearance of clinical nephropathy. Later in the course of the
nephropathy in patients the filtering surface area becomes
reduced, an anatomic change yet to be demonstrated in ani-
mals, and associated with serious impairment of renal function
[25].
Good glycemic control from the onset of diabetes tends to
inhibit the development of nephropathy in rats [26—28] and, as is
clear from the present studies, also in dogs. The nephropathy
observed in animals kept in poor glycemic control cannot be
attributed therefore simply to nephrotoxic effects of alloxan or
aging. These findings lead one to hope that the development of
diabetic nephropathy in patients also might be inhibited by
improvement of glycemic control, at least if good control is
established soon after the onset of diabetes. The evidence that
the nephropathy can be inhibited by good glycemic control
provides no information as to whether the inhibition is due to
correction of the hyperglycemia itself, or is due instead to the
coincident correction of other metabolic sequelae of deficient
insulin activity (dysmetabolism of lipids, proteins, etc.). Hyper-
glycemia, although an appropriate target for clinical treatment,
is of uncertain significance in the pathogenesis of nephropathy.
In contrast to the marked nephropathy observed in diabetic
dogs after five years of hyperglycemia, kidneys from dogs
experimentally galactosemic equally long seem little affected.
Glomerular volume as well as the volume of the mesangium and
cellular components of the tuft, and the capillary filtering
surface area are not abnormal in galactosemic dogs, and clearly
are less affected than in diabetes. The results of the present
ultrastructural analysis are consistent with our observations by
light microscopy [13]. By light microscopy, the mesangial area
(estimated semi-quantitatively), frequency of obliterated gb-
meruli, and kidney weight were found to be normal in experi-
mental galactosemia, and significantly less than in diabetes.
Nonetheless, the basement membrane of glomerular capillaries
is found by us to be significantly thickened by experimental
galactosemia. This basement membrane thickening occurs in
the absence of any increase whatever in mesangial matrix, a
basement membrane-like material known to become excessive
in diabetes. Accumulation of mesangial matrix therefore seems
unlikely to be produced by the same sequelae of hyperglycemia
that cause accumulation of basement membrane in the capillary
wall. Similarly, abnormalities of the glomerular capillary base-
ment membrane and mesangial matrix in diabetic animals have
been reported to be not equally reversible by islet transplanta-
tion [15, 18].
Dogs made experimentally galactosemic for several years
develop a retinopathy that is remarkably similar to that seen in
diabetic patients and diabetic dogs [12]. The retinopathy in-
cludes saccular capillary aneurysms, pericyte "ghosts", non-
perfused acellular capillaries, and hemorrhage. Thus, galac-
tosemia sufficient to produce diabetic-like lesions in the
glomerular basement membrane and retina has proved to be not
sufficient to elicit several renal abnormalities that are typical of
diabetes, notably mesangial expansion, glomerular hypertrophy
and obliteration, and nephromegaly.
Consumption of the galactose-rich diet results in elevation of
the blood levels of an isomer of glucose (galactose) in the
apparent absence of many other metabolic abnormalities of
diabetes, such as insulinopenia and supranormal blood levels of
glucose, fatty acids, branched-chain amino acids and fibrinogen
[12]. Diabetic-like lesions produced by feeding the galactose
appear to be secondary to the hyperglycemia (galactosemia)
itself and its sequelae.
Two sequelae of hyperglycemia, excessive non-enzymatic
glycation of protein and excessive production or accumulation
of polyol, have received much attention in recent years, and the
magnitude of each in our galactosemic animals appears to be
unlike that in our insulin-deficient animals. Tissue levels of
non-enzymatically glycated protein, represented in the present
study by HbA1, tend to be less in galactosemic dogs than in
insulin-deficient dogs. This may be due in part to a difference in
severity of hyperglycemia, since blood hexose levels in insulin-
deficient dogs tend to remain elevated at all hours of the day,
whereas in galactose-fed dogs the blood hexose rises postpran-
dially but subsequently approaches normal during sleep or
fasting.
Tissue polyol concentration, in contrast, tends to be greater
in galactosemic dogs than in insulin-deficient dogs, as shown for
renal cortex in the present study and for erythrocytes in a prior
study [13]. Excessive production and accumulation of polyols
has been implicated in capillary basement membrane thickening
in diabetes and experimental galactosemia, inasmuch as the
thickening in retinal vessels of diabetic and galactose-fed rats
reportedly can be prevented by administration of an aldose
reductase inhibitor [29—31]. Comparison of the effects of exper-
imental galactosemia and diabetes described herein and in a
previous report [131 raise a possibility, however, that mesangial
expansion, glomerular hypertrophy and obliteration, and seem-
ingly other renal lesions typical of diabetes are not a result of
excessive tissue polyol concentrations alone, and thus may
respond less well than perhaps other diabetic complications to
treatment with aldose reductase inhibitors.
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